Infection in the elderly: studies with lomefloxacin

Area of Science:

• Pharmacology
• Infectious Diseases
• Geriatrics

Background:

• Elderly patients often present unique challenges in managing infections due to age-related physiological changes.
• Urinary tract infections (UTIs), chronic bronchitis exacerbations, and surgical prophylaxis are common clinical scenarios in geriatric populations.

Purpose of the Study:

• To analyze the efficacy and safety of lomefloxacin in elderly patients across various infections.
• To compare lomefloxacin's performance against standard treatments in different geriatric patient groups.

Main Methods:

• Analysis of clinical trial data for lomefloxacin (400 mg once daily or single dose) in elderly patients (≥65 years).
• Inclusion of patients with uncomplicated and complicated UTIs, acute bacterial exacerbations of chronic bronchitis, and those undergoing transurethral surgery.
• Comparison of bacterial eradication rates and clinical efficacy with comparator agents and across age groups.

Main Results:

• Lomefloxacin achieved 100% bacterial eradication in elderly patients with uncomplicated UTIs.
• In complicated UTIs, lomefloxacin (92.2%) showed statistically superior eradication compared to comparators (84.9%, p=0.012).
• For chronic bronchitis exacerbations, lomefloxacin (85.2%) was more effective than amoxicillin (73.8%, p=0.004); it was 98% effective for surgical prophylaxis.

Conclusions:

• Lomefloxacin demonstrates significant efficacy in treating various infections in elderly patients.
• The drug's effectiveness in older adults is comparable to that observed in younger patient populations.
• Lomefloxacin is a viable therapeutic option for UTIs, bronchitis exacerbations, and surgical prophylaxis in the elderly.